Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Pollen Allergenic Extract [EPC]
Fraxinus Americana Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of White Ash pollen allergies through skin testing and subcutaneous immunotherapy.
Name
Fraxinus Americana Pollen
Raw Name
FRAXINUS AMERICANA POLLEN
Category
Non-Standardized Pollen Allergenic Extract [EPC]
Drug Count
27
Variant Count
29
Last Verified
February 17, 2026
About Fraxinus Americana Pollen
Fraxinus Americana Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of White Ash pollen allergies through skin testing and subcutaneous immunotherapy.
Detailed information about Fraxinus Americana Pollen
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Fraxinus Americana Pollen.
As a non-standardized extract, the potency of Fraxinus Americana Pollen is typically expressed in terms of weight/volume (w/v) or protein nitrogen units (PNU), rather than bioequivalent allergy units (BAU). This distinction is critical for healthcare providers to understand, as it influences how the dosage is escalated during treatment. The FDA has regulated allergenic extracts for decades, with many of these products remaining on the market under established safety and efficacy profiles for the management of seasonal allergic rhinitis (hay fever) and allergic asthma.
To understand how Fraxinus Americana Pollen works, one must first understand the pathophysiology of an allergy. When a sensitized individual inhales White Ash pollen, their immune system—specifically IgE antibodies—recognizes the proteins in the pollen as a threat. This triggers the degranulation of mast cells and basophils, releasing inflammatory mediators like histamine and leukotrienes, which cause sneezing, itching, and airway swelling.
In a diagnostic setting, a small amount of the extract is introduced into the skin. If the patient has pre-existing IgE antibodies to White Ash, a localized 'wheal and flare' reaction occurs within minutes. In a therapeutic setting, known as subcutaneous immunotherapy (SCIT), the extract is injected in gradually increasing doses. This process aims to shift the immune response from a Th2-dominated (allergic) response to a Th1-dominated or T-regulatory (Treg) response. Over time, the body increases the production of 'blocking antibodies' (IgG4), which intercept the allergen before it can bind to IgE, thereby reducing the severity of allergic symptoms upon natural exposure.
Unlike traditional synthetic drugs, allergenic extracts like Fraxinus Americana Pollen do not follow standard pharmacokinetic pathways involving systemic absorption, distribution, metabolism, and excretion in the traditional sense. Instead, their 'pharmacokinetics' are better described as immunological processing.
Fraxinus Americana Pollen extracts are FDA-approved for the following indications:
Off-label, some clinicians may use these extracts in modified rapid 'rush' immunotherapy protocols, though this carries a significantly higher risk of systemic reactions and must be performed in highly controlled environments.
Fraxinus Americana Pollen is primarily available in the following forms:
> Important: Only your healthcare provider can determine if Fraxinus Americana Pollen is right for your specific condition. The selection of the appropriate concentration and the decision to proceed with immunotherapy require an extensive evaluation by a board-certified allergist or immunologist.
The regulation of allergenic extracts like Fraxinus Americana Pollen is unique. Many of these extracts were grandfathered into use before the modern, rigorous clinical trial requirements for new molecular entities. However, the FDA's Allergenic Products Advisory Committee continually reviews these products to ensure that the manufacturing processes—including the source materials (raw pollen) and extraction methods—meet strict purity and identity standards. The 'non-standardized' label reflects the biological complexity of the pollen, which contains dozens of different proteins, making it difficult to assign a single unit of potency that applies to all patients equally.
Dosage for Fraxinus Americana Pollen is highly individualized and is divided into two distinct phases: the Build-up Phase and the Maintenance Phase.
During the build-up phase, the healthcare provider starts with a very dilute concentration (e.g., 1:100,000 or 1:10,000 w/v). Injections are typically administered once or twice a week. The dose is gradually increased with each injection, provided the patient does not experience significant local or systemic reactions. This phase usually lasts 3 to 6 months.
Once the 'maintenance dose' is reached—which is the highest dose the patient can tolerate without significant side effects—the frequency of injections is reduced. Maintenance injections are typically given every 2 to 4 weeks. The goal is to maintain this level of exposure for 3 to 5 years to achieve long-term immunological tolerance.
Fraxinus Americana Pollen is used in children, generally starting at age 5. The dosing logic is similar to that of adults, based on sensitivity and tolerance rather than body weight. However, clinicians must exercise extreme caution in young children who may not be able to communicate early symptoms of a systemic reaction (anaphylaxis). Immunotherapy is generally not recommended for children under the age of 5 because of the difficulty in monitoring and the potential for severe reactions.
No specific dosage adjustments are required for patients with renal impairment, as the extract is not cleared by the kidneys in a manner that leads to toxicity.
No dosage adjustments are needed for hepatic impairment.
Elderly patients (over 65) require careful evaluation. While the dose is not adjusted based on age alone, the presence of comorbid conditions like cardiovascular disease may make the use of epinephrine (the treatment for a reaction) more dangerous. Therefore, the starting dose may be more conservative.
Fraxinus Americana Pollen is NEVER for self-administration at home. It must be administered by a healthcare professional in a clinical setting equipped to handle anaphylaxis.
In immunotherapy, timing is critical. If a dose is missed during the build-up phase, the next dose may need to be reduced to the previous level to prevent a reaction. If a dose is missed during the maintenance phase by more than a week or two, the allergist will typically reduce the dose and then gradually build it back up. Never attempt to 'double up' on a dose to make up for a missed one.
An 'overdose' in the context of allergenic extracts usually refers to a dosage escalation that is too rapid for the patient's immune system to handle, or an accidental administration of the wrong concentration.
If an overdose is suspected, the immediate administration of epinephrine is required. The patient should be placed in a recumbent position and monitored for further respiratory or cardiac distress. Emergency medical services (911) should be contacted immediately if the reaction occurs outside the immediate presence of the treating physician.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or the frequency of your visits without medical guidance, as this significantly increases the risk of a life-threatening reaction.
The most frequent side effects associated with Fraxinus Americana Pollen are localized to the site of injection. These are often considered a normal part of the body's immune response to the extract.
> Warning: Stop taking Fraxinus Americana Pollen and call your doctor immediately or seek emergency care if you experience any of the following symptoms of anaphylaxis:
When administered correctly, Fraxinus Americana Pollen does not typically cause long-term organ toxicity. The primary 'long-term' effect is the desired one: a permanent or semi-permanent reduction in allergic sensitivity. However, there is a theoretical risk that repeated immune stimulation could play a role in autoimmune processes, though this has not been definitively proven in large-scale clinical studies of allergen immunotherapy.
Fraxinus Americana Pollen extracts carry a Black Box Warning regarding the risk of severe systemic reactions.
Report any unusual symptoms, even if they seem minor, to your healthcare provider. A small reaction today could be the precursor to a larger reaction at the next appointment.
Fraxinus Americana Pollen is a potent biological agent. Its use requires strict adherence to safety protocols to prevent life-threatening complications. Patients must be honest with their doctors about their current health status, including whether they are currently experiencing a 'flare' of their allergy symptoms or asthma, as this significantly increases the risk of a reaction to the injection.
No FDA black box warnings for Fraxinus Americana Pollen. (Note: While many standardized extracts have them, non-standardized extracts are always treated with the same level of clinical caution. The primary warning is for Anaphylaxis Risk.) All allergenic extracts are required to carry warnings that they can cause severe, life-threatening systemic reactions. This includes the requirement that the drug only be administered in a setting where emergency resuscitative equipment and trained personnel are immediately available.
Generally, Fraxinus Americana Pollen does not cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have fully recovered and been cleared by a physician.
Alcohol consumption should be avoided for several hours before and after an injection. Alcohol can increase blood flow to the skin and potentially speed up the absorption of the allergen, increasing the risk of a reaction.
Immunotherapy is a long-term commitment. Stopping the injections suddenly will not cause 'withdrawal' in the traditional sense, but it will result in the loss of the immunological progress made. If you stop for a period of time and wish to restart, you cannot start at your previous dose; you must go back to a safer, lower concentration to avoid a reaction.
> Important: Discuss all your medical conditions, especially heart or lung problems, with your healthcare provider before starting Fraxinus Americana Pollen.
While there are few 'absolute' drug-drug contraindications, certain combinations are avoided due to safety concerns:
There are no direct food-drug interactions with Fraxinus Americana Pollen. However, patients should avoid heavy exercise or hot showers immediately after an injection, as these activities increase systemic circulation and can lead to faster absorption of the allergen.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially if you have recently started a new medication for blood pressure or depression.
Fraxinus Americana Pollen must NEVER be used in the following circumstances:
These conditions require a careful risk-benefit analysis by the allergist:
White Ash (Fraxinus americana) is in the Oleaceae family. Patients who are allergic to White Ash may also show sensitivity to other members of this family, including:
This cross-reactivity is important for the allergist to consider when formulating a multi-allergen extract for the patient.
> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and cardiovascular health, before prescribing Fraxinus Americana Pollen.
Fraxinus Americana Pollen is categorized as Pregnancy Category C. This means there are no adequate and well-controlled studies in pregnant women.
It is generally considered safe to continue Fraxinus Americana Pollen immunotherapy while breastfeeding. The large protein molecules in the extract are unlikely to pass into breast milk in any significant quantity, and even if they did, they would be digested by the infant's gastrointestinal tract.
No dose adjustment is required for patients with kidney disease. The proteins are processed locally by the immune system and do not rely on renal filtration for clearance.
No dose adjustment is required for patients with liver disease. The extract does not undergo hepatic metabolism via the cytochrome P450 system.
> Important: Special populations require individualized medical assessment. Always inform your allergist if you become pregnant or develop new health problems during the course of your treatment.
Fraxinus Americana Pollen works through a process of 'immunological desensitization.' The extract contains the major allergen Fra a 1, a protein that is recognized by the immune system.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous administration) |
| Protein Binding | N/A (Processed by immune cells) |
| Half-life | Hours (for the proteins), Years (for the immune memory) |
| Tmax | 30-60 minutes (for local absorption) |
| Metabolism | Proteolysis by Antigen Presenting Cells |
| Excretion | Cellular degradation/clearance |
Fraxinus Americana Pollen is classified as a Non-Standardized Pollen Allergenic Extract. It is part of a broader group of biologicals used for the management of Type I hypersensitivity disorders. Related medications include standardized grass extracts (e.g., Timothy grass) and other tree extracts (e.g., Oak, Birch).
Common questions about Fraxinus Americana Pollen
Fraxinus Americana Pollen extract is primarily used for the diagnosis and treatment of allergies to White Ash tree pollen. In diagnostic settings, it is used in skin prick tests to identify if a patient has a specific IgE-mediated sensitivity to this pollen. For treatment, it is used in allergen immunotherapy, commonly known as allergy shots, to desensitize the patient's immune system over time. This helps reduce symptoms of hay fever, allergic conjunctivitis, and allergic asthma triggered by ash trees. It is an essential tool for patients who do not find sufficient relief from standard allergy medications like antihistamines.
The most common side effects are localized reactions at the site of the injection, including redness, swelling, and itching. These reactions usually appear shortly after the injection and resolve within a few hours to a day. Some patients may also experience a temporary increase in their typical allergy symptoms, such as sneezing or watery eyes. While rare, systemic reactions like hives or mild wheezing can occur. Because of the risk of more severe reactions, patients must always be monitored for 30 minutes following administration. Any significant swelling at the injection site should be reported to the allergist before the next dose.
It is generally advised to avoid alcohol consumption on the day of your allergy injections. Alcohol can cause vasodilation, which increases blood flow to the skin and may accelerate the absorption of the pollen extract into the bloodstream. This rapid absorption can increase the risk of a systemic allergic reaction or anaphylaxis. Furthermore, alcohol can sometimes mask the early symptoms of a reaction, making it harder for you or your doctor to identify a problem. To ensure maximum safety, wait at least several hours after your injection before consuming alcohol. Always check with your specific healthcare provider for their clinic's policy.
The safety of starting Fraxinus Americana Pollen immunotherapy during pregnancy has not been established, and it is generally avoided. The main concern is not that the extract will harm the fetus directly, but that a severe allergic reaction (anaphylaxis) in the mother could lead to a dangerous drop in oxygen levels for the baby. However, if a woman is already on a stable maintenance dose of allergy shots and becomes pregnant, many allergists will continue the treatment because the risk of a reaction is much lower at that stage. The decision to continue must be made after a thorough discussion between the patient, their allergist, and their obstetrician. Dose increases are typically avoided during pregnancy.
Allergen immunotherapy is a slow process and does not provide immediate relief like an antihistamine or a nasal spray. Most patients enter a 'build-up phase' that lasts three to six months, during which the dose is gradually increased. Significant improvement in allergy symptoms is usually noticed toward the end of this phase or early in the 'maintenance phase.' It typically takes a full year of treatment to see the maximum benefit during the White Ash pollen season. For long-lasting results that continue even after the shots are stopped, a total treatment course of three to five years is generally recommended. Consistency with the injection schedule is key to achieving these results.
Yes, you can stop taking the injections suddenly without experiencing physical withdrawal symptoms, as the extract is not an addictive substance. However, stopping the treatment will halt the process of desensitization, and your allergy symptoms will likely return to their previous severity over time. If you stop for several weeks or months and then decide to restart, you cannot simply resume at your last dose. Your immune system's tolerance will have decreased, and restarting at a high dose could cause a dangerous reaction. Your doctor will need to restart you at a much lower concentration and gradually build the dose back up safely.
If you miss a scheduled injection, you should contact your allergist's office as soon as possible to reschedule. Do not attempt to make up for the missed dose by taking a higher dose later. The management of a missed dose depends on how long it has been since your last injection and whether you are in the build-up or maintenance phase. If only a few days have passed, the doctor may give you your usual dose. If several weeks have passed, the doctor will likely need to reduce your dose for safety and then gradually increase it again. Following the prescribed schedule is the best way to ensure the treatment is both safe and effective.
There is no clinical evidence to suggest that Fraxinus Americana Pollen extracts cause weight gain. The extract consists of natural proteins and a small amount of stabilizer (like glycerin or phenol), none of which have metabolic effects that would lead to increased body fat or appetite. If you experience weight gain while undergoing immunotherapy, it is likely due to other factors, such as lifestyle changes, other medications (like oral steroids sometimes used for asthma), or an unrelated medical condition. You should discuss any unexpected weight changes with your primary care physician to determine the underlying cause.
Fraxinus Americana Pollen can be taken alongside most common medications, but there are important exceptions. You must inform your doctor if you are taking beta-blockers or ACE inhibitors for blood pressure, as these can make allergic reactions more dangerous and harder to treat. Antihistamines and other allergy medications are often continued during immunotherapy, though they must be stopped several days before diagnostic skin testing to ensure accurate results. Some antidepressants, specifically MAOIs and TCAs, can also interact with the emergency medications used to treat a severe reaction. Always provide your allergist with a complete and updated list of all medications and supplements you are using.
The concept of 'generic' drugs does not apply to allergenic extracts in the same way it does to synthetic pills. Fraxinus Americana Pollen is a biological product produced by several different licensed laboratories. While the extracts from different manufacturers are similar, they are 'non-standardized,' meaning the exact protein concentration and potency can vary between brands. For this reason, allergists generally prefer to stick with the same manufacturer's extract for a patient's entire course of treatment. If a switch between manufacturers is necessary, the doctor will often reduce the dose significantly to ensure safety, as the new extract might be more potent than the previous one.